Sec Form 13D Filing - Frazier Life Sciences IX, L.P. filing for - 2026-01-27

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D



Comment for Type of Reporting Person:
The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The amounts reported in rows 8, 10 and 11 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See Item 5(a) to this Statement. The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The amounts reported in rows 8, 10 and 11 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See Item 5(a) to this Statement. The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The amounts reported in rows 8, 10 and 11 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See Item 5(a) to this Statement. The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The shares listed in rows 8, 10 and 11 represents (i) 3,566,912 shares of Common Stock held directly by Frazier Life Sciences IX, L.P., and (ii) 459,010 shares of Common Stock held directly by Frazier Life Sciences X, L.P. The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, and (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The shares listed in rows 8, 10 and 11 represents (i) 5,703 shares of Common Stock held directly by the Reporting Person, (ii) 76,779 shares of Common Stock that are issuable upon the exercise of options held directly by the Reporting Person, (iii) 3,566,912 shares of Common Stock held directly by Frazier Life Sciences IX, L.P., and (iv) 459,010 shares of Common Stock held directly by Frazier Life Sciences X, L.P. The percentage listed in row 13 is calculated based on the sum of (i) 51,393,574 shares of Common Stock outstanding on October 31, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 4, 2025, (ii) 5,196,009 shares of Common Stock that were anticipated to be issued in connection with the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iii) 2,385,149 shares of Common Stock that were anticipated to be issued by the Issuer in a private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 8, 2025, (iv) 1,000,000 shares of Common Stock that were anticipated to be issued by the Issuer in an additional private placement transaction immediately following the acquisition of Bluejay Therapeutics, Inc., as set forth in the Issuer's Current Report on Form 8-K filed with the SEC on December 19, 2025, and (v) 76,779 shares of Common Stock that are issuable upon the exercise of options held directly by the Reporting Person.


SCHEDULE 13D

 
Frazier Life Sciences IX, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS IX, L.L.C., GP of FHMLS IX, L.P., GP of Frazier Life Sciences IX, L.P.
Date:01/27/2026
 
FHMLS IX, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS IX, L.L.C., GP of FHMLS IX, L.P.
Date:01/27/2026
 
FHMLS IX, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS IX, L.L.C.
Date:01/27/2026
 
Frazier Life Sciences X, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:01/27/2026
 
FHMLS X, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:01/27/2026
 
FHMLS X, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS X, L.L.C.
Date:01/27/2026
 
Frazier Life Sciences Public Fund, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:01/27/2026
 
FHMLSP, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:01/27/2026
 
FHMLSP, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:01/27/2026
 
Frazier Life Sciences XI, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:01/27/2026
 
FHMLS XI, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:01/27/2026
 
FHMLS XI, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:01/27/2026
 
Frazier Life Sciences XII, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date:01/27/2026
 
FHMLS XII, L.P.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
Date:01/27/2026
 
FHMLS XII, L.L.C.
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, CFO of FHMLS XII, L.L.C.
Date:01/27/2026
 
James N. Topper
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to Power of Attorney
Date:01/27/2026
 
Patrick J. Heron
 
Signature:/s/ Jennifer Martin
Name/Title:By Jennifer Martin, Attorney-in-Fact for Patrick J. Heron, pursuant to Power of Attorney
Date:01/27/2026
primary_doc.xml